In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bial Trial Tragedy: No Safety Clue From Similar Products

This article was originally published in Scrip

Executive Summary

Though officially unconfirmed, it is presumed that the fatty acid amide hydrolase inhibitor at the center of the Bial clinical trial disaster is BIA 10-2474, which was in Phase I development for the treatment of "neurological and psychiatric pathologies". But there were few clues to its potential toxicity from previous products with this mechanism of action investigated, and dropped from development.






Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts